CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more
CannBioRx Life Sciences Corp - Asset Resilience Ratio
CannBioRx Life Sciences Corp (ATNFW) has an Asset Resilience Ratio of 93.46% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2019)
This chart shows how CannBioRx Life Sciences Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CannBioRx Life Sciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.30 Billion | 93.46% |
| Total Liquid Assets | $10.30 Billion | 93.46% |
Asset Resilience Insights
- Very High Liquidity: CannBioRx Life Sciences Corp maintains exceptional liquid asset reserves at 93.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CannBioRx Life Sciences Corp Industry Peers by Asset Resilience Ratio
Compare CannBioRx Life Sciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for CannBioRx Life Sciences Corp (2017–2019)
The table below shows the annual Asset Resilience Ratio data for CannBioRx Life Sciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 22.89% | $11.88 Million | $51.88 Million | -76.88pp |
| 2018-12-31 | 99.77% | $118.17 Million | $118.44 Million | +0.17pp |
| 2017-12-31 | 99.60% | $116.59 Million | $117.06 Million | -- |